Company Overview and News

 
Explaurum rejects Ramelius offer

2018-10-12 businessnews.com.au
The board of Explaurum has rejected a $59.2 million hostile takeover bid from gold miner Ramelius Resources, saying the offer is opportunistic and undervalues the target.
RMS RMLRF

 
Ramelius Resources commences $59m takeover of Explaurum

2018-09-27 australianmining.com.au
Ramelius Resources has launched a takeover process for gold explorer Explaurum Limited with the distribution of a bidder’s statement and acceptance form.
RMS EVN BOK CAHPF RMLRF

 
Cygnus Gold identifies multiple VMS targets at Burracoppin polymetallic project

2018-09-19 proactiveinvestors.com.au
Cygnus Gold Ltd (ASX:CY5) has defined 14 high-priority targets through a ground gravity survey at the Anomaly 47 prospect within its Burracoppin Project in Western Australia’s southwest.
RMS RMLRF

 
Ramelius to head underground

2018-09-18 businessnews.com.au
Gold producer Ramelius Resources has announced plans to commence underground mining at its Edna May operation near Southern Cross early next year.
RMS RMLRF

 
Ramelius commits to early 2019 start for Edna May gold mine

2018-09-18 australianmining.com.au
Ramelius Resources is to commence underground mining at the Edna May gold mine near Westonia, Western Australia in early 2019.
RMS EVN CAHPF RMLRF

 
Ramelius lobs $59m Explaurum bid

2018-09-10 businessnews.com.au
Ramelius Resources has launched a $59.2 million hostile takeover bid for exploration company Explaurum, which is aiming to develop its Tampia Hill gold project in the Wheatbelt.
RMS RMLRF

 
Explaurum surges 50% on takeover offer from Tampia Hill neighbour Ramelius Resources

2018-09-10 proactiveinvestors.com.au
Explaurum Ltd (ASX:EXU) is a leading ASX gainer with shares up almost 50% after fielding a takeover offer from Ramelius Resources Limited (ASX:RMS).
RMS EXU RMLRF

 
Evolution Mining in record territory despite production fall

2018-08-17 australianmining.com.au
Evolution Mining may have logged a fall in gold production during the 2018 financial year but the miner still has plenty to cheer about in other areas of its performance.
RMS EVN CAHPF RMLRF

1
Diggers and Dealers Mining Forum gold plays to make up 21% of presenters

2018-08-05 proactiveinvestors.com.au
Diggers and Dealers Mining Forum 2018 will welcome a pack of gold plays to the stage this week to speak about their companies and the precious metal. Here’s who’s going.
ELKMF OCANF PILBF RMS EVN GCY SCEXF SNDFY WAF NST DCN AU IGO AULGF RSG OGC GOR LONCF MSR RMGGF SFR SBM AGG CAHPF PLS WFRSF IIDDY RGRNF ORG PNR LN NESRF SFRRF RMGGY RRL OGDCF NHRNY CANWF RMLRF SAR

 
Diggers and Dealers chairman expects ‘buoyant’ forum

2018-08-01 proactiveinvestors.com.au
Diggers and Dealers Mining Forum will attract some higher profile Australian mining companies to Kalgoorlie-Boulder next week, with the forum’s chairman tipping a ‘buoyant’ Diggers with great presentations.
NCMGF PILBF NCM RMS GCY EVN SCEXF SNDFY NST DCN IGO AGY ARYMF RSG MMI RMGGF SFR SBM CAHPF FMG WNARF WSA PLS IIDDY FSUGY NESRF NCMGY FSUMF SFRRF RMGGY NHRNY PEX RMLRF SAR

 
Element 25 selling non-core Holleton Gold Project to focus on manganese

2018-07-30 proactiveinvestors.com.au
Element 25 Ltd (ASX:E25) is selling its non-core Holleton Gold Project in Western Australia to Ramelius Resources Limited’s (ASX:RMS) wholly-owned subsidiary Edna May Operations Pty Ltd (EMO).
RMS MZM RMLRF

 
Ramelius Resources boosts cash and gold reserves by $20 million in June quarter

2018-07-10 proactiveinvestors.com.au
Ramelius Resources Limited (ASX:RMS) (FRA:RRZ) has increased its cash and gold at bank to $95.5 million after producing 58,285 ounces of gold in the June 2018 quarter.
RMS RMLRF

 
Gateway Mining’s 24.2 g/t of gold over 4 metres reveals potential new discovery at Gidgee project

2018-07-10 proactiveinvestors.com.au
Gateway Mining Ltd (ASX:GML) believes a 4-metre intersection grading 24.2 g/t gold from 241 metres indicates the potential for a new high-grade discovery at the Gidgee Gold Project in Western Australia.
GML BKHRF RMS BLK RMLRF

2
Ramelius Resources exceeds March quarter guidance on way to 200,000 ounces in 2018

2018-04-09 proactiveinvestors.com.au
The company’s production of 58,671 ounces in the March 2018 quarter from its three projects in Western Australia was a record.
RMS RMLRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: Q7982E108